Eli Lilly's financial reports or industry sales reports

Tirzepatide Reduces Heart Failure Risk by 38% in Obese Patients with HFpEF, SUMMIT Trial Shows

Nov 16, 2024, 03:02 PM

Clinical trials have demonstrated that tirzepatide, a dual GIP/GLP-1 receptor agonist developed by Eli Lilly, significantly improves cardiovascular outcomes in patients with obesity and heart failure with preserved ejection fraction (HFpEF). The SUMMIT trial, involving 731 individuals with HFpEF and a body mass index over 30, showed that tirzepatide led to a 38% reduction in the risk of death from cardiovascular causes or worsening heart-failure events compared to placebo. The trial had a median follow-up of 104 weeks, and over 50% of participants were women. The hazard ratio was 0.62 for the composite endpoint of worsening heart failure or cardiovascular death. Notably, consistent benefits were observed even in patients with NT-proBNP levels below 200 pg/mL. This marks a significant advancement in treating HFpEF, as it is the first trial demonstrating hard outcomes benefit of GLP-1 receptor agonists in heart failure.